Andecaliximab, also known as GS-5745, represents a valuable scientific tool within the field of immunological analyses. This humanized monoclonal immunoglobulin selectively interacts with CD40 ligand (CD40L), a crucial molecule involved in immune responses. By preventing CD40L binding with its target, andecaliximab offers investigators a means to assess the part of this pathway in various disease models and organic processes . Its applicability is particularly noted in understanding the mechanisms underlying tissue dismissal and certain body-attacking disorders . Therefore, andecaliximab serves as a key asset for advancing our knowledge of the intricacies of the protective system.
Andecaliximab: Unveiling Potential in Scientific Studies
GS-5745, also known as the antibody Andecaliximab , represents a notable area of current research. Originally developed as an anti-GPIIb/IIIa clinical substance, its peculiar mechanism of attaching to platelets opens valuable avenues for expanded exploration beyond its original clinical indication . Investigators are increasingly directing on its usefulness in studying platelet behavior and potential roles in various condition models . Furthermore , GS-5745's ability to uniquely target platelet adherence makes it a important resource for advanced life science investigations.
Clarifying This Molecule for Specific Study
The identification of {Andecaliximab | the experimental compound | this molecule, designated by the CAS number 1518996-49-0, represents a crucial stage for directed exploration. This unique identifier allows researchers to reliably locate pertinent information regarding its structure , mode of operation , and potential benefits in medical settings . Concentrating studies on Andecaliximab, using this concise substance identification, will expedite a deeper knowledge of its properties and projected influence on illness intervention. Continued work with 1518996-49-0 anticipates notable advances in the area of targeted therapy .
GS-5745 Research: Examining this antibody's Potential
Current research concerning {Andecaliximab | the anti-CD40 agent , the therapy , are aimed at completely understanding its capabilities in combating multiple autoimmune diseases . Notably, initial here findings show that GS-5745 may interfere key systemic pathways involved in disease development. Planned clinical evaluations will attempt to confirm these early results and clarify the ideal dosage and individual cohort that might profit from this promising medical method.
```text
{GS-5745: A Thorough Look into this Substance for Study
GS-5745, currently known as Andecaliximab, represents a notable experimental approach targeting GPI-anchored protein GPCR family involved in platelet adhesion and reaction. Investigators are actively employing this engineered immunoglobulin for initial studies evaluating its efficacy in various disease domains, particularly those involving clot-related events . Ongoing work concentrates on understanding the exact pathway of impact and assessing optimal dosing methods . Additional analysis is required to entirely evaluate its tolerability profile and real-world positives.
- Purpose in in vitro analyses
- Assessment of bodily answer
- Possible part in therapy of cardiovascular problems
```
```text
Andecaliximab: Utilizing Substance 1518996-49-0 in Laboratory Settings
Andecaliximab, also identified by the substance designation 1518996-49-0, has developed as a important instrument in contemporary laboratory environments. Investigators are actively studying its potential as an protein, particularly concerning its mode of action impacting blood cell aggregation. Early data suggest that this substance holds potential for expanded research aimed at clarifying condition pathways and creating innovative medical approaches.
```